Yagudin, T,
Zhao, Y,
Gao, HY,
Zhang, Y,
Yang, Y,
Zhang, XF,
Ma, WB,
Daba, TM,
Ishmetov, V,
Kang, K,
Yang, BF,
Pan, ZW (2021) infarction in order to facilitate the development of novel therapy.
Inhibitor of apoptosis
Лечение метастатическогогепатоцеллюлярного рака ленватинибом.Клинический случай и обзор литературыMenshikov, K.V.,
Sultanbaev, A.V.,
Akhmetgareeva, K.T.,
Lipatov, D.O.,
К.В. Меньшиков,
А.В. Султанбаев,
К.Т. Ахметгареева,
Д.О. Липатов (2021) . Lenvatinib is a ty-rosine kinase
inhibitor for the treatment of advanced HCC that is not subject to local
Роль мутаций в гене NF1 в спорадическом канцерогенезе protooncogenes). To overcome the resistance of these neoplasms,
inhibitors of mitogen-activated protein kinase
Guan, XX,
Zhang, YW,
Gareev, I,
Beylerli, O,
Li, XY,
Lu, GT,
Lv, L,
Hai, X (2021) completely reversed the inflammatory response. Knockdown of miR-499a by its specific
inhibitor in healthy